Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma

NCT01026051 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Financial/Business Reasons

Conditions

Stage III Melanoma
Stage IV Melanoma

Interventions

BIOLOGICAL: MKC1106-MT

Sponsor

Mannkind Corporation